To study whether radical nephrectomy (RN) with lymph node dissection (LND) can benefit pT3 renal cell carcinoma (RCC) patients versus no LND under the 2018 American Joint Committee on Cancer TNM classification system. Subjects/Patients and Methods: We performed a retrospective cohort study of clinicopathological data for 245 T3 RCC patients, who underwent radical nephrectomy between January 2006 and December 2013 at our center, including 67 (27.1%) who underwent LND. The relationships between the LND and progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) were evaluated using 1:1 propensity score (PS) matching. Then, Kaplan-Meier survival analysis and Cox regression analysis were conducted to study whether these patients can benefit from LND. Depending on the LND number, we divided the cohort into two groups for further comparation. At last, we validated the results with the TCGA database KIRC patients.

The median follow-up time was 4.9 years. Sixty-seven pairs of patients were screened by the PS and were further analyzed. We conducted a Cox regression with the survival data and found that the LND group, compared with the non-LND group, showed no survival benefit on PFS, CSS, and OS (p = 0.444, 0.809, and 0.816, respectively). However, the removal of 5 or more LNs showed negative effect on OS (p = 0.0387). TCGA cohort results are mostly consistent with our findings.

RN with LND cannot improve the PFS, CSS, or OS for pT3 renal cell carcinoma patients.

Journal of Cancer. 2019 May 26*** epublish ***

Pin Li, Cheng Peng, Liangyou Gu, Yongpeng Xie, Wenyuan Nie, Yu Zhang, Yundong Xuan, Donglai Shen, Songliang Du, Lu Tang, Yuanxin Yao, Yang Fan, Xin Ma, Xu Zhang

School of Medicine, Nankai University, Tianjin, People’s Republic of China., Department of Urology, State Key Laboratory of Kidney Diseases, the First Medical Center of Chinese PLA General Hospital, Beijing, People’s Republic of China., Department of Urology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China., Department of Urology, Chinese People’s Liberation Army, 89th Hospital, Weifang, Shandong, People’s Republic of China.